USFDA pulls up Jagsonpal Pharmaceuticals for manufacturing lapses at API plant

The USFDA has issued a warning to Jagsonpal Pharmaceuticals following an inspection of its API plant in Rajasthan. The regulator highlighted significant deviations from Current Good Manufacturing Practice, including inadequate quality systems and non-compliance. Jagsonpal must address these issues and ensure future compliance to avoid potential repercussions.

from Industry-Economic Times https://ift.tt/IFdfPBA
via IFTTT